Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo visualization of PARP inhibitor pharmacodynamics

21 Apr 2021

Abstract excerpt

BACKGROUND[18F]FluorThanatrace ([18F]FTT) is a radiolabeled poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that enables noninvasive quantification of PARP with potential to serve as a biomarker for patient selection for PARPi therapy. Here we report for the first time to our knowledge noninvasive in vivo visualization of drug-target engagement during PARPi treatment.METHODSTwo single-arm,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Toxin Mechanisms and Immunotoxins
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33884961
DOI: 10.1172/jci.insight.146592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo visualization of PARP inhibitor pharmacodynamicsPMID 33884961Read ↗

[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancerSemantic proximity Read ↗

Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib.Semantic proximity Read ↗

Molecular Imaging of PARPSemantic proximity Read ↗

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic ProbesSemantic proximity Read ↗

A Radiotracer Strategy to Quantify PARP-1 Expression <i>In Vivo</i> Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor TherapySemantic proximity Read ↗

[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.Semantic proximity Read ↗

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseSemantic proximity Read ↗

Molecular Imaging: PARP-1 and BeyondSemantic proximity Read ↗

Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations.Semantic proximity Read ↗

The evolving landscape of predictive biomarkers of response to PARP inhibitorsSemantic proximity Read ↗

A PET imaging agent for evaluating PARP-1 expression in ovarian cancerSemantic proximity Read ↗

A novel <sup>18</sup> F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.